Organon & Co. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations
Organon & Co. (OGN) had Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations of $706.00 million as of 2022-12-31, per its 10-K filed 2023-02-27.
Discontinued › Cash Flow › Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations · last filed 2023-02-27
- 2022-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations $706.00M.
- 2022-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations $499.00M.
- 2022-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations $545.00M.
- 2022-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations $694.00M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations |
|---|---|
| 2022-12-31 | $706.00M 10-K · filed 2023-02-27 |
| 2022-09-30 | $499.00M 10-Q · filed 2022-11-04 |
| 2022-06-30 | $545.00M 10-Q · filed 2022-08-05 |
| 2022-03-31 | $694.00M 10-Q · filed 2022-05-06 |
| 2021-12-31 | $737.00M 10-K · filed 2023-02-27 |
| 2021-09-30 | $1.01B 10-Q · filed 2022-11-04 |
| 2021-06-30 | $730.00M 10-Q · filed 2022-08-05 |
| 2021-03-31 | $161.00M 10-Q · filed 2022-05-06 |
| 2020-12-31 | $70.00M 10-K · filed 2023-02-27 |
| 2020-09-30 | $381.00M 10-Q · filed 2021-11-12 |
| 2020-06-30 | $444.00M 10-Q · filed 2021-08-16 |
| 2020-03-31 | $320.00M 10-Q · filed 2021-06-21 |
| 2019-12-31 | $319.00M 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |